scholarly journals PROLONGATION OF SURVIVAL OF GASTRIC CANCER PATIENTS WITH PARAAORTIC LYMPH NODES METASTASIS THROUGH COMBINATION THERAPY WITH CONTINIOUS 5-FLUOROURACIL AND LOW DOSE (DAILY) CISPLATIN

1999 ◽  
Vol 60 (6) ◽  
pp. 1449-1453
Author(s):  
Tadahiko OGAWARA ◽  
Akira MAKI ◽  
Mamoru OKAZAKI ◽  
Yasuoki KIJIMA ◽  
Nobuhiko KAMITA ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Combination Therapy ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Low Dose ◽  
Lymph Nodes Metastasis ◽  
Paraaortic Lymph Nodes ◽  
Gastric Cancer Patients

The prognostic significance of isolated tumor cells in the lymph nodes of gastric cancer patients

2010 ◽  
Vol 13 (3) ◽  
pp. 191-196 ◽  
Author(s):  
Takeo Fukagawa ◽  
Mitsuru Sasako ◽  
Seiji Ito ◽  
Hayao Nakanishi ◽  
Hisae Iinuma ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Prognostic Significance ◽  
Isolated Tumor Cells ◽  
Gastric Cancer Patients

Clinical Relevance of Occult Tumor Cells in Lymph Nodes From Gastric Cancer Patients

2005 ◽  
Vol 29 (9) ◽  
pp. 1135-1144 ◽  
Author(s):  
Fania S Doekhie ◽  
Wilma E Mesker ◽  
J Han J. M. van Krieken ◽  
Niels F. M Kok ◽  
Henk H Hartgrink ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Clinical Relevance ◽  
Occult Tumor ◽  
Gastric Cancer Patients ◽  
Occult Tumor Cells

The Prognostic Significance of the Number of Resected Lymph Nodes in Gastric Cancer Patients

2009 ◽  
Vol 9 (4) ◽  
pp. 246 ◽  
Author(s):  
Se Jin Kim ◽  
You Jin Jang ◽  
Jong Han Kim ◽  
Sung Soo Park ◽  
Seong Heum Park ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Gastric Cancer Patients

KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15503-e15503
Author(s):  
G. Stella ◽  
F. Rojas Llimpe ◽  
C. Barone ◽  
A. Falcone ◽  
F. Di Fabio ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Combination Therapy ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Objective Response ◽  
Locally Advanced ◽  
Braf Mutations ◽  
Exon 2 ◽  
Mutational Status ◽  
Gastric Cancer Patients

e15503 Background: The prognosis of advanced gastric cancer (GC) patients (pt) is still poor despite the introduction of new chemotherapy regimens. In colorectal cancer (CRC) it has been demonstrated that KRAS or BRAF mutations are associated with resistance to treatment with the anti-EGFR mAbs. We have assessed whether, and to what extent, the mutational profile of KRAS and BRAF genes affects the response to cetuximab combination therapy in GC. Methods: We have collected 44 tumor samples from pts affected by locally advanced or metastatic GC undergoing cetuximab combination therapy as first-line treatment in two consecutive phase II studies. Thirteen pts received cetuximab plus FOLFIRI (FOLCETUX Study) and 31 pts cetuximab plus cisplatin and docetaxel (DOCETUX Study). Genomic DNA was extracted from paraffin-embedded tumor specimens from all cases. The mutational status of KRAS (exon 2) and BRAF (exon 15) was ascertained by PCR amplification followed by direct sequencing. The objective response was evaluated every 6 weeks by CT according to RECIST criteria. Results: KRAS and BRAF mutations were detected in 5 (11.4%) and 1 (2.3%), respectively, of the 44 tumors analyzed. These frequencies are consistent with those previously reported in GC. In the case of KRAS, 3 cases displayed amino acid substitutions of codon 12 and 1 of codon 13. One case had the A11V variant that had been reported in hematopoietic and lymphoid tissue of the stomach. The only BRAF mutation found in 1 sample was the classic V600E substitution. As a whole, 13.6 % of the analyzed tumors carried a mutation in either KRAS or BRAF genes. K-RAS and BRAF mutations were, as expected, mutually exclusive. In this pt cohort oncogenic activation of KRAS/BRAF-signaling pathways was not significantly associated to objective response (p= 0.757). Also, we found no correlation between KRAS/BRAF mutations and clinical outcome measured as overall survival. Conclusions: In advanced GC the frequency of mutations in KRAS and BRAF is lower as compared with CRC cancer. In our cases, the mutational status of KRAS and BRAF genes does not correlate with the response to cetuximab-based therapy in advanced gastric cancer patients. No significant financial relationships to disclose.

Minimum Number of Removed and Examined Lymph Nodes is Essential in Gastric Cancer Patients: Reply to Letter

2010 ◽  
Vol 34 (5) ◽  
pp. 1138-1139 ◽  
Author(s):  
Corrado Pedrazzani ◽  
Daniele Marrelli ◽  
Armands Sivins ◽  
Franco Roviello
Keyword(s):  
Gastric Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Minimum Number ◽  
Gastric Cancer Patients

2031 Number of retrieved lymph nodes in gastric cancer patients and survival

2015 ◽  
Vol 51 ◽  
pp. S338
Author(s):  
N. Saraiva ◽  
A.R. Garcia ◽  
A. Nogueira ◽  
N. Bonito ◽  
P Jacinto ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document